Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer.

IF 1 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Nuklearmedizin-nuclear Medicine Pub Date : 2023-02-01 DOI:10.1055/a-1984-8044

Huipan Liu, Xiao Yang, Zhouxiang You, Zhi Hu, Yue Chen

{"title":"Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer.","authors":"Huipan Liu, Xiao Yang, Zhouxiang You, Zhi Hu, Yue Chen","doi":"10.1055/a-1984-8044","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the clinical value of 68Ga-FAPI-04 PET/CT for initial staging of esophageal cancer.Methods: A total of 44 newly diagnosed patients with esophageal cancer were included in the analysis on the basis of postoperative pathology or clinical and radiologic follow-up.Results: All primary lesions showed increased 68Ga-FAPI-04 uptake, with an SUVmax of 14.92 ± 6.91. A total of 561 lymph nodes were verified by surgery (507) or clinical and radiologic follow-up (54), of which 92 lymph nodes were diagnosed as showing metastases. Seventy-five lymph nodes with metastases showed positive findings on 68Ga-FAPI-04, with a diameter of about 1.06 ± 0.53 cm and SUVmax of 8.10±4.71. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for lymph node metastasis detection were 81.5%, 99.3%, 96.6%, 96.2%, and 96.5%, respectively.Conclusion: 68Ga-FAPI-04 PET/CT showed good diagnostic performance in detecting lymph node metastases of esophageal cancer.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"38-44"},"PeriodicalIF":1.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1984-8044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 2

Abstract

Aim: To investigate the clinical value of 68Ga-FAPI-04 PET/CT for initial staging of esophageal cancer.

Methods: A total of 44 newly diagnosed patients with esophageal cancer were included in the analysis on the basis of postoperative pathology or clinical and radiologic follow-up.

Results: All primary lesions showed increased 68Ga-FAPI-04 uptake, with an SUVmax of 14.92 ± 6.91. A total of 561 lymph nodes were verified by surgery (507) or clinical and radiologic follow-up (54), of which 92 lymph nodes were diagnosed as showing metastases. Seventy-five lymph nodes with metastases showed positive findings on 68Ga-FAPI-04, with a diameter of about 1.06 ± 0.53 cm and SUVmax of 8.10±4.71. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for lymph node metastasis detection were 81.5%, 99.3%, 96.6%, 96.2%, and 96.5%, respectively.

Conclusion: 68Ga-FAPI-04 PET/CT showed good diagnostic performance in detecting lymph node metastases of esophageal cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

68Ga-FAPI-04 PET/CT在食管癌早期分期中的作用

目的:探讨68Ga-FAPI-04型PET/CT对食管癌早期分期的临床价值。方法:对44例新诊断食管癌患者进行术后病理或临床及影像学随访分析。结果:所有原发病变68Ga-FAPI-04摄取增加，SUVmax为14.92±6.91。共561个淋巴结经手术(507个)或临床及影像学随访(54个)证实，其中92个淋巴结被诊断为转移。68Ga-FAPI-04阳性淋巴结75例，直径约1.06±0.53 cm, SUVmax为8.10±4.71。检测淋巴结转移的敏感性为81.5%，特异性为99.3%，准确性为96.6%，阳性预测值为96.2%，阴性预测值为96.5%。结论:68Ga-FAPI-04型PET/CT对食管癌淋巴结转移有较好的诊断价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nuklearmedizin-nuclear Medicine 医学-核医学

CiteScore

1.70

自引率

13.30%

发文量

267

审稿时长

>12 weeks

期刊介绍： Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar. Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab. Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben. Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.

期刊最新文献

The Medical Informatics Initiative and the Network University Medicine - Perspectives for Nuclear Medicine. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC. NuklearMedizin 2024: Abstract-Einreichung bis zum 1. November geöffnet! DGN-Forschungs- und -Förderpreise Preisverleihungen